Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally.
FAIL · Does not pass the screen
8.10 USD
Price as of 30 Oct 2026Daily close, not a live quote
Screened 2026-10-30 · the tape above runs as of 14:01 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.70, read 2026-10-29
Ethical does not pass the values gate
Price8.10 USD
Fair value11.73
Ethical score70.0/100
Our investment reviews on this name
2026-10-17Read Accumulation7.17+13.0% to today ✓Markdown gives way to Accumulation after an 11% slide in 7 weeks
2026-08-31Read Markdown8.09+0.1% to today Markup gives way to Markdown after an 11% rise in 4 weeks
2026-07-31Read Markup7.27+11.4% to today ✓Accumulation gives way to Markup with deal news in the headlines
2026-07-02Read Accumulation7.64+6.0% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Grifols, S.A. holds its Accumulation at $8.10. Consolidating, no directional conviction, held for 56 days.
As held on the ledger · 2026-10-30
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 56 days
Price at the screen
$8.10
Valuation
9.67 trailing · 5.23 forward price to earnings
Values screen
FAIL· score 70.0
Beta
1.20
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
48.53%
Below 33%
Interest-bearing debt is 48.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
1.83%
Below 33%
Cash held in interest-bearing accounts and securities is 1.8% of assets, under the one-third limit.
Pass
Receivables
7.37%
Below 49%
Money owed to the company is 7.4% of assets, under the 49% limit.
Pass
Revenue purity
0.45%
Below 5%
Only 0.5% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Grifols,'s business is in a permissible area, but its interest-bearing debt is about 49% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-31. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when GRFS's ethical verdict changes
Today GRFS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-30 screen. The gold marker is the market price at the same screen. A 44.8% margin of safety to the base estimate.
Third-party analyst targets: 2 covering, consensus Buy. The average target sits +34% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-30 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Cheap plasma stock masks falling revenues and thin returns
Grifols collects and processes blood plasma into medicines that treat immune disorders and other serious conditions. The shares sit at just 5 times forward earnings with a 61 percent gap to our fair value estimate, yet revenue has already dropped 5 percent and returns on equity remain stuck at 6 percent.
We pass because the numbers show a business that is shrinking, not compounding. Low profit margins and an unknown competitive edge leave little room for the kind of durable cash flow that would justify stepping in, even after the ethical screen clears.
Risk sits mainly around execution in a fragmented plasma market and the chance that current earnings already reflect peak volumes rather than a lasting floor. Two analysts still see upside to 11 dollars, but the flat growth trajectory keeps us on the sidelines. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: its business and earnings are exposed to Spain and to currency swings; as a drug manufacturers - general name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GRFS trades on Nasdaq (the company is based in Spain). As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-31Accumulation$7.56+0.3%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-10-24Accumulation$7.54+5.2%Entry 8
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-10-17Accumulation · changed$7.17-1.8%Entry 7
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 1.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-10-02Markdown$7.30-9.8%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 9.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-08-31Markdown · changed$8.09+11.3%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 11.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-07-31Markup · changed$7.27-4.8%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 4.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-07-18Accumulation$7.64+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 18%. Our forward projection puts the odds of a 10% gain over the next month near 26%. The street (2 analysts) rates it none, with a mean price target of $11.
2026-07-03Accumulation$7.64+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02Accumulation$7.64Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
